Evidence map›Paper›PMID 36629182›Full record

ArticleThe Indian journal of medical research2022

Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.

Amarendra Mahapatra, Subrata Kumar Palo, Debdutta Bhattacharya, Srikanta Kanungo, Jaya Singh Kshatri, Bijaya Kumar Mishra, Asit Mansingh, Debaprasad Parai, Matrujyoti Pattnaik, Hari Ram Choudhary and 8 more

Abstract read
In one paragraph

Article in The Indian journal of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Amarendra MahapatraICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Subrata Kumar PaloICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Debdutta BhattacharyaICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Srikanta KanungoICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Jaya Singh KshatriICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Bijaya Kumar MishraICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Asit MansinghICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Debaprasad ParaiICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Matrujyoti PattnaikICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Hari Ram ChoudharyICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Girish Chandra DashICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Amiya Ranjan MohantaICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Anjan BishoyeeICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Prasantajyoti MohantyICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Nityananda MandalICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Rakesh DayalDepartment of State TB Training and Demonstration Centre, National Health Mission, Government of Jharkhand, Ranchi, Jharkhand, India.
Anindya MitraICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Sanghamitra PatiICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & objectives: Serosurvey of COVID-19 provides a better estimation of people who have developed antibodies against the infection. Undertaking such a serosurvey in certain districts of India which are densely populated with prominent tribes can provide valuable information regarding seropravelance of SARS-CoV-2 antibodies among such indigenous populations. In this context, two rounds of population-based, cross-sectional serosurveys for SARS-CoV-2 IgG antibody were carried out in Jharkhand, a tribal-dominated State of India, to compare the seroprevalence of SARS-CoV-2 infection and to determine the associated demographic risk factors. Methods: The surveys were carried out in June 2020 and February 2021 in ten districts of the State of Jharkhand. Blood samples were collected from the residents of the selected districts by random sampling and tested for anti-SARS-CoV-2 antibodies using an automated chemiluminescence immunoassay platform. A total of 4761 and 3855 eligible participants were included in round 1 and round 2, respectively. Results: The age- and gender-standardized seroprevalence for COVID-19 during round 1 was 0.54 per cent (0.36-0.80) that increased to 41.69 per cent (40.16-43.22) during round 2 with a gap of eight months in between. The seropositivity among male and female participants was 0.73 and 0.45 per cent, respectively, during the first round and 51.35 and 33.70 per cent, respectively, during the second round. During the first round, 17.37 per cent of the participants were tribal with seropositivity of 0.24 per cent (0.02-0.87), and during the second round, 21.14 per cent were tribal with seropositivity of 39.14 per cent (35.77-42.59). Compared to tribal group, non-tribal participants had an adjusted odds of 1.24 (95% confidence interval=1.04-1.48) for SARS-CoV-2 seropositivity. Interpretation & conclusions: COVID-19 seroprevalence was found to be low during the first round (0.54%) of the survey, possibly due to the travel restrictions during lockdown better adherence to social distancing and wearing of face masks among the people. Understanding the dynamics of SARS-CoV-2 transmission and the susceptibility to infection at the individual as well as community level will inform decision and help policy makers to design and implement effective public health strategies to mitigate the pandemic in this State.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralCommunicable Disease ControlCross-Sectional StudiesFemaleHumansImmunoglobulin GIndiaMaleSeroepidemiologic StudiesAntibodies, ViralImmunoglobulin GCOVID-19seronegativeseropositiveseroprevalencetribal population

Identifiers

PMID36629182
PMCPMC10057356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.